Irresectable intrahepatic cholangiocellular carcinoma:Evaluation of the Efficacy of multimodal treatment by interstitial HDR-Brachytherapy combined with Gemcitabine/Cisplatin Chemotherapy - CHOICE II

niversitätsklinikum Magdeburg0 个研究点目标入组 50 人开始时间: 2016年8月10日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•histologically confirmed cholangiocellular carcinoma
•intrahepatic localization of a massforming CCC
•whole tumor bound of the liver not > 50%
•at least 1 lesion is accessible to an interventional therapy
•consent and ability to all study specific actions voluntary, informed and personally written consent
•Patient Age not under 18 and not over 85 years
•suitable cardiac, renal and haematological parameters

•pregnant or breast-feeding women respectively possible pregnancy
•uncontrolled ascites
•other tumor diseases within the last 5 years (expect carcinoma in situ of the skin or zervix)
•uncooperative/noncompliant
•already participant of this study
•participation on another therapy study
•contraindication for Primovist-MRI or contrast-CT
•moderate or graved renal failure (GFR < 60 ml/min) appropriate to laboratory values 1 week before Primovist-MRI
•previous Radiation of the liver
•to clinic or investigator related patients
•acute or risk of acute severe bleeding (WHO grade 3-4)
•upper gastrointestinal bleeding in the last 3 month
•thrombembolic events including TIA in the last 6 month
•uncontrolled hypertonus
•life expactancy under 16 weeks
•state by orgn transplantation
•congenital immune defects
•immunsuppressive therapie in case of autoimmune disease or chronic inflammatory disease

发起方

niversitätsklinikum Magdeburg